Par Pharma begins shipping generic Sabril in USA

Par Pharmaceuticals, an operating company of Ireland-incorporated Endo International (Nasdaq: ENDP), has begun shipping vigabatrin for oral solution USP, 500mg per packet following final approval from the US Food and Drug Administration for its Abbreviated New Drug Application.

Par's vigabatrin for oral solution is the generic version of Danish CNS specialist Lundbeck’s (LUND: CO) anti-epileptic drug Sabril and is the first and currently the only generic version available.  Vigabatrin is available only through certified healthcare providers and specialty pharmacies.

"We are pleased to be able to offer patients a cost-effective option to Sabril," said Tony Pera, president of Par Pharmaceutical, adding: "Par's vigabatrin for oral solution is therapeutically equivalent to the brand and is therefore substitutable. We are proud to continue our tradition at Par of providing high quality, affordable medicines."